Fate Therapeutics Inc (FATE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $138.71M
Last updated: Nov 17, 2026 at 4:15 PM ET
Fate Therapeutics Inc (FATE) Statistics
Fate Therapeutics (FATE) has a market cap of $138.71M and an enterprise value of $164.15M. It kept -2619.64% of revenue as net income over the last 12 months. Revenue fell 33.45% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 18.34% above the market cap, as debt exceeds cash.
| Market Cap | $138.71M |
|---|---|
| Enterprise Value | $164.15M |
| Latest price (Nov 17, 2026) | $1.02 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 26.6x and 0.9x. Its year-end P/S ranged from 5.8x to 245.1x from 2016 to 2025.
| P/S Ratio | 26.6x |
|---|---|
| Forward P/S | 39.2x |
| P/B Ratio | 0.9x |
Price Statistics
The stock is up 5.81% over 52 weeks and trades 51.43% below its 50-day average.
| Beta (1Y) | 2.31 |
|---|---|
| 52-Week Change | +5.81% |
| 1-Month Change | -45.16% |
| 3-Month Change | -61.51% |
| 6-Month Change | -46.03% |
| 5-Year Change | -96.13% |
| 10-Year Change | -0.95% |
| Total Return (1Y) | +5.81% |
| Total Return (3Y CAGR) | -25.12% |
| Total Return (5Y CAGR) | -54.98% |
| Return vs SPY (1Y) | -11.56% |
| Max Drawdown (1Y) | -67.20% |
| Max Drawdown (3Y) | -91.86% |
| Sharpe Ratio (1Y) | 0.00 |
| Correlation with SPY (1Y) | 0.35 |
| 50-Day Average | $2.10 |
| 200-Day Average | $1.98 |
| 52-Week Range | $0.95 to $3.23 |
| RSI (14 Days) | 19.3 |
| Average Volume (20 Days) | 1.66M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.41x current liabilities, and total debt is 0.52x shareholder equity.
| Current Ratio | 4.41x |
|---|---|
| Quick Ratio | 4.41x |
| Debt / Equity | 0.52x |
Returns and Efficiency
Return on invested capital is -51.32% over the last 12 months, against a 5-year average of -35.15%.
| Return on Equity (ROE) | -93.54% |
|---|---|
| Return on Assets (ROA) | -52.22% |
| Return on Invested Capital (ROIC) | -51.32% |
| ROE (5Y Average) | -51.48% |
| ROA (5Y Average) | -35.95% |
| ROIC (5Y Average) | -35.15% |
| Asset Turnover | 0.02x |
| Receivables Turnover | 8.04x |
Scores
FATE has an Altman Z-Score of -10.08, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.08 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $4.75M over the last 12 months.
| Revenue | $4.75M |
|---|---|
| Revenue Growth (YoY) | -33.45% |
| Gross Profit | $4.75M |
| Operating Income | -$131.10M |
| Pretax Income | -$124.43M |
| Net Income | -$124.43M |
| EBITDA | -$123.18M |
| Reported EPS (TTM) | -$1.03 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 55.83% of the $238.28M in total assets.
| Cash and Equivalents | $43.94M |
|---|---|
| Total Debt | $69.38M |
| Net Debt | $25.44M |
| Net Debt Per Share | $0.21 |
| Working Capital | $111.57M |
| Shareholder Equity | $133.03M |
| Book Value Per Share | $1.08 |
| Total Assets | $238.28M |
| Total Liabilities | $105.24M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$105.46M |
|---|---|
| FCF Per Share | -$0.89 |
| Depreciation and Amortization | $14.58M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2760.04%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2760.04% |
| Pretax Margin | -2619.64% |
| Net Margin | -2619.64% |
| EBITDA Margin | -2593.35% |
Growth
Revenue fell 58.98% a year over 3 years.
| Revenue Growth (3Y CAGR) | -58.98% |
|---|---|
| Revenue Growth (5Y CAGR) | -26.71% |
| Book Value Per Share Growth (2Y CAGR) | -31.67% |
| Tangible Book Per Share Growth (2Y CAGR) | -31.67% |
Dividends and Yields
FATE does not pay a dividend.
| Buyback Yield | 0.00% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 7 similar companies, FATE has the highest P/S.
P/S RatioPeer median 4.0x
ROICPeer median -149.78%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -28.56%
| P/S Ratio | 26.6x vs 4.0x median |
|---|---|
| ROIC | -51.32% vs -149.78% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -33.45% vs -28.56% median |
Analyst Forecast
Consensus estimates put revenue growth at -31.96% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -31.96% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About FATE
What is FATE's market cap?
Fate Therapeutics has a market cap of $138.71M. Its enterprise value, which adds debt and subtracts cash, is $164.15M.
How many shares of FATE are outstanding?
Fate Therapeutics has 123.66M shares outstanding. The count is up 3.91% from a year earlier.
Does FATE pay a dividend?
No. Fate Therapeutics does not pay a dividend.
How much debt does FATE have?
Fate Therapeutics has $69.38M of total debt and $43.94M of cash and equivalents, a net debt position of $25.44M.
FATE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors